The Bermuda Triangle may not be the biggest mystery of the Atlantic. In a new study published in the journal Geophysical Research Letters, scientists believe they have discovered the reason why ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

A thick layer of more than 12 miles of rock may explain why Bermuda seems to float above the surrounding ocean. When you purchase through links on our site, we may earn an affiliate commission. Here’s ...

Dec 8 (Reuters) - Structure Therapeutics (GPCR.O), opens new tab said on Monday its obesity pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study, driving the company ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Structure Therapeutics ...

OpenAI announced Tuesday morning that it had completed a tumultuous corporate restructuring effort, simplifying a complex ownership web into a controlling nonprofit entity and a reimagined for-profit ...

Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through at ...

Former Colorado Republican Vice Chairwoman Hope Scheppelman is looking to unseat Jeff Hurd as the Republican representing Colorado’s 3rd Congressional District in the U.S. House. Scheppelman, who ...

Antibodies that bind to two targets are an established way of treating the blood cancer multiple myeloma. Aiming to top those medicines, AbbVie has secured rights to an early-clinical drug that works ...

AbbVie is paying Ichnos Glenmark Innovation (IGI) $700 million upfront for a next-generation rival to Johnson & Johnson’s Tecvayli, positioning the Big Pharma to advance a new option for multiple ...

Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 ...